Objectives: Iminoral is the generic microemulsion of cyclosporine. We performed a randomized double-blind multicenter trial to evaluate its efficacy and safety compared with the innovator medication Neoral for preventing acute rejection episodes in adult patients during the first year after renal transplant.
Materials and Methods: We used 221 de novo renal transplant recipients from 6 transplant centers in Iran enrolled between April 2008, and January 2010. They were randomized to receive either Iminoral or Neoral as the calcineurin inhibitor component of the immunosuppressive regimen in addition to mycophenolate mofetil and oral corticosteroids. They were followed-up for 1 year. The primary endpoint was the rate of acute allograft rejection. Secondary endpoints consisted of 1-year graft survival rates, daily dosages of cyclosporine, trough and C2 cyclosporine blood level, serum creatinine levels, patient death rates, discontinuing the study drug, tolerability, and adverse events.
Results: The risk of acute rejection episode during the first month after transplant was 9% for Iminoral and 10% for Neoral; these declined to 4% and 2% during next 11 months. One-year graft survival rate was 0.86 for both groups. Renal function stabilized during the first month. Declination of the creatinine levels was similar between the 2 groups and reached a stable value of 114.9 μmol/L five months after the transplant. The frequency of clinical complications was similar between the groups.
Conclusions: Iminoral is safe and effective when used in de novo kidney transplant patients as an immunosuppressive medication.
Key words : Graft rejection, Iran, Calcineurin inhibitors
Cyclosporine is a calcineurin inhibitor that has been used since 1983. It is one of the most widely used immunosuppressive drugs for an organ transplant. Although new immunosuppressive drugs and protocols, with the lower incidences of transplant rejection and toxicity have been emerged in last decades,1-4 cyclosporine is still the most frequently given in immunosuppressive regimens in renal transplant.5-7
Iminoral is the first generic microemulsion-based formulation of cyclosporine, developed by Zahravi Pharmaceutical Company in Iran, and it has been approved by the appropriate regulatory authorities. It has been available since 2003. Its bioequivalence to the innovator drug Neoral in healthy volunteers has been shown previously. The bioavailability parameters (Cmax, Tmax, t1/2, AUC0-12, and AUC0-∞) of both formulations are similar and within FDA specified limits.8,9 Furthermore, Iminoral possesses equal efficacy and safety when compared with Neoral in stable adult renal transplant recipients who have been switched from Neoral to Iminoral.9 At present, Iminoral covers more than 90% of Iranian medicine market of cyclosporine. It is 50% less expensive than Neoral. This offers a substantial cost-savings to transplant patients and to the health care system.
However, no study has been performed yet to verify the efficacy and safety of Iminoral in de novo renal transplant recipients. This study was conducted to evaluate the clinical outcomes of Iminoral consumption for 1 year after transplant.
Materials and Methods
Design and enrollment
This clinical trial is registered at http://clinicaltrial/ ct2/show/record/ NCT00656695. The protocol was approved by the Review Board and ethics committee of Tehran University of Medical Sciences (#S68463/February 2008), and it conforms to the 1975 Declaration of Helsinki. Written, informed consent was obtained from all patients after educating them about the nature and details of the study.
The study was begun on April 21, 2008, and ended on January 20, 2010, at which time all of the patients had reached 1 year of follow-up. In this double-blind study, among 385 candidates for kidney transplant in 6 kidney transplant centers in Iran (Isfahan, Shiraz, Mashhad, Kerman, and 2 centers in Tehran), 221 patients were enrolled in the study after meeting the inclusion criteria. Inclusion criteria were that all adult kidney transplant candidates were at least 18 years old. Exclusion criteria were hyperoxaluria and primary focal segmental glomerulosclerosis, multiorgan transplant, history of malignancy in the previous 5 years, retransplant, and panel reactivity that was more than 25%.
To preserve the double-blind condition, Iminoral and Neoral soft gelatin capsules (in 2 dosage forms: 100 mg and 25 mg) were blister packed with identical appearance, distinct batch numbers, and expiration date. Each blister was labeled according to the balanced block randomization method prepared by each center, separately. Patients were randomly assigned to receive either Iminoral or Neoral, using a computer-generated list of random numbers. Neither the prescriber nor the patient could recognize the brand of cyclosporine. Batch numbers were kept in confidence in a warehouse of the Zahravi Pharmaceutical Company until the end of study. After the statistical analyses of data, medications were decoded.
Currently in Iran, human leukocyte antigen matching for living-unrelated kidney donors is not performed, and just white blood cell cross-match is mandatory.10,11 All patients were ABO compatible and received induction therapy with polyclonal antibodies, and antihuman thymocyte globulin (ATG) if they received the allograft from brain-dead donors, or if their serum creatinine levels decreased more than 50% after the first postoperative day. Antihuman thymocyte globulin was given according to manufacturer’s recommendations. The treatment protocol was a triple immunosuppressive regimen that included cyclosporine, mycophenolate mofetil, and corticosteroids. Diltiazem was in the maintenance protocol, routinely, to make the dosage of cyclosporine less expensive. The dosage of cyclosporine was 6 to 8 mg/kg twice a day, which was tapered to 4 mg/kg/d by 2 weeks, according to the whole blood cyclosporine level, and the patient’s clinical assessment. The first initial dosage was administered 12 hours before kidney transplant. In those with ATG, the dosage starts with 3 mg/kg/d, and after stopping the ATG, the dosage increased to 4 to 5 mg/kg/d.
The target level of cyclosporine was set to 300 ng/mL for cyclosporine trough concentration (C0) and 1200 to 1500 ng/mL for cyclosporine 2-hour postdose concentration (C2) for the first 14 days after transplant. The C0 level of 150 to 350 ng/mL, and C2 level of 800 to 1200 ng/mL were maintained for the first 2 months. From the second until the sixth month, the C0 level of 100 to 250 ng/mL and C2 level of 800 to 1200 ng/mL were maintained, and since that time, the C0 level of 100 ng/mL and C2 level of 500 to 800 ng/mL was achieved. Corticosteroid therapy was started with an intravenous pulse of 500 mg methylprednisolone before the transplant and continued with oral prednisolone 1 mg/kg, which was rapidly tapered to 0.1 mg/kg during next 3 months. Mycophenolate mofetil was given 2 g/d in 2 divided doses. If postoperative acute tubular necrosis occured, or if renal function detoriorated because of other nonimmunologic events, ATG was administered according to manufacturer's recommendations until the patient’s renal function improved (an increase in urine volume and a decrease in the serum level of creatinine). Meanwhile, cyclosporine consumption was terminated, and the dosage of mycophenolate mofetil was reduced to 500 mg/d.
Acute rejection was managed with intravenous methylprednisolone 500 mg pulse therapy for 3 days. If a satisfactory response was not achieved, ATG was administered according to the manufacturer's recommendations. Acute rejection episodes were diagnosed by the presence of the following: increase in the serum creatinine level to 30% over baseline, substantial medical imaging results (eg, ultrasound and isotope scanning), exclusion of other causes of renal function impairment (eg, drug toxicity, infection, homodynamic instability, obstruction, inflammation, or vascular disorder), and biopsy-proven episodes. A kidney allograft biopsy was performed only if acute rejection criteria mentioned above were not fulfilled, or if the antirejection therapy did not improve the renal function. Diltiazem was the first choice in hypertensive patients, and other medications were prescribed according to the patient’s history and physician’s decision.
Monitoring of efficacy and safety
All patients were followed for 1 year after the transplant. The primary endpoint of the study was defined as the rate of graft rejection occurrence, during the first year after transplant. Secondary endpoints consisted of graft loss, increase in daily dosages of cyclosporine, decrease in trough and C2 cyclosporine blood levels, increase of serum creatinine levels, death rate, discontinuation of the study drug, tolerability, and adverse events. Efficacy and safety were monitored by visiting the patients daily for first 2 weeks, and then weekly until the eighth week, and monthly thereafter. Cyclosporine blood levels were measured during the first, second, and eighth weeks, and during the third, sixth, and 12th months after transplant, and whenever it was necessary according to the physician's decision.
Categorical data are expressed as frequency and percentage. Quantitative data are summarized as means ± standard deviation; otherwise specified. One patient in the Neoral group, and 2 patients in the Iminoral group did not take their allocated drugs until the end of study; however, analyses of the data were performed based on the intent-to-treat population. To compare the distribution of categorical variables between the study groups, the chi-square and the Fisher exact tests were used (when appropriate). The unpaired t test was used to compare distribution of continuous variables. We calculated the graft survival rate by measuring the time between the transplant and acute rejection, or the last contact (if no rejection occurred). To compare survival rates, we performed Kaplan-Meyer estimates and log-rank test. P values less than .05 were considered statistically significant. For those variables that were measured repeatedly, a P value less than .01 was considered statistically significant.
The study population was composed of 221 randomized patients (111 patients in the Iminoral group, and 110 patients in the Neoral group). Of these, 203 patients (91.8%) completed the 12-month study (Figure 1). Baseline characteristics were similar between groups (Table 1).
Table 2 shows the cyclosporine levels in the 2 treatment groups during the study. Mean cyclosporine C0 and C2 levels remained within the target range at all time points in the Iminoral and the Neoral groups, except during the 12th month, when C0 level was above the target range (100 ng/mL) in both groups (152.79 ± 56.35 and 176.1 ± 81.18 ng/mL for the Neoral and the Iminoral groups). Though the same dosages of cyclosporine were administered to both groups, the C0 level in the Iminoral group was higher than that of the Neoral group during entire the study (P = NS). In the Iminoral group, the C2 level also was higher than it was in the Neoral group (but not significantly) except in weeks 2 and 8.
Efficacy and graft function
One-year graft survival rate without rejection was 0.86 in both the Iminoral and the Neoral groups (log-rank test; P =.89; Figure 2). The rate of acute rejection in the groups showed no significant differences during the 12 months of the study (Table 3). In 3 cases of acute rejection (2 in the Neoral group, and 1 in the Iminoral group) methylprednisolone pulse therapy was ineffective, and ATG was administered. No case of acute rejection resulted in the discontinuation from the study procedures. Cyclosporine C0 and C2 levels at the time of acute rejection were not significantly different between the groups (C0: 211.5 ± 88.3 ng/mL in the Neoral group vs 234.0 ± 201.6 ng/mL in the Iminoral group; C2: 978.0 ± 306.0 ng/mL in the Neoral group vs 741.9 ± 376.54 ng/mL in the Iminoral group).
Mean serum creatinine levels were similar in both the Neoral and the Iminoral groups (Table 4) indicating good kidney graft function during 12 months of the study. The mean serum creatinine level at the time of acute rejection was 300.5 ± 123.7 μmol/L in the Neoral group and 260.7 ± 70.7 μmol/L in the Iminoral group.
The most frequently seen adverse events were hyperglycemia, hypertension, infection, abdominal discomfort, nausea, and tremor (Table 5) with a similar distribution in each group. No adverse events led to discontinuation of the study. Transplant surgery complications occurred 1 day after surgery in 2 patients in the Neoral group, and in 1 patient in the Iminoral group. Tacrolimus had to be administered to these patients. One case of graft loss occurred in Neoral group the day after transplant.
There were 2 deaths during the study. One patient in the Iminoral group died 4 months after the transplant because of bacterial pneumonia and septicemia. One patient in the Neoral group died 2 weeks after the transplant because of sepsis and disseminated intravascular coagulation.
Hospital readmission occurred in 71 patients (32.1%), with a similar distribution in each group (37 in the Neoral group [16.7%], and 34 in the Iminoral group [15.4%]). The causes included kidney dysfunction, abdominal pain, flulike symptoms, uncontrolled hypertension, acne, urinary infection, hyper-glycemia, and tremor (Table 6).
The results of the current randomized double-blind multicenter trial study revealed that de novo use of Iminoral from the time of the transplant results in good graft and patient survival rates. One-year graft survival rate without rejection was 0.86 in the Iminoral group, which is similar to the Neoral group. The risk of an acute rejection episode in the first month after transplant was 9% in the Iminoral group, declining to 4% during the following 11 months. These values are similar to the data obtained for the Neoral group with the rates of 10% and 2%. These results indicate that the efficacy of Neoral is comparable to Iminoral when used in renal transplant patients.
Renal function stabilized between months 1 and 12 in both groups. The trend of decline in the serum creatinine level was similar between the groups during the study, and the level reached a stable value of 114.9 μmol/L at month 5 after transplant.
Findings of the present work extend the results of previous studies comparing bioavailability and efficacy of Iminoral versus Neoral in healthy volunteers,8 and stable renal transplant patients who were switched from Neoral to Iminoral.9 Despite administering the same doses of cyclosporine to both groups, patients in the Iminoral group experienced higher but not significant C0 and C2 levels during treatment. We did not find such a result with Iminoral in the previous studies we performed in healthy volunteers and stable renal transplant patients.8,9
Regarding the adverse effects, the significant adverse effect was hypertension. Some may argue that diltiazem, which increase cyclosporine levels, may be involved in the increase in the rate of hypertension. However, the main objective of this study was to compare the 2 brands of drugs, and it seems that administering diltiazem, which interferes with cyclosporine metabolism, does not have any negative effect on the results.
In conclusion, to our knowledge, this is the first study to be performed with a generic cyclosporine formulation on de novo kidney transplant patients using a double-blind design and a considerable sample size. The high rate of 1-year graft survival, we found, and the low risk of acute rejection and good safety profile associated with Iminoral, suggests that this generic formulation can be substituted for innovator medication Neoral in immunosuppressive drug regimens for renal transplant patients.
Volume : 13
Issue : 3
Pages : 233 - 238
DOI : 10.6002/ect.2013.0139
From the 1Nephrology Research Center, Tehran University of Medical
Sciences, Tehran; the 2Kidney Transplant Center of Zahra Hospital,
Isfahan University of Medical Sciences, Isfahan; the 3Kidney
Transplant Center of Afzali-pour Hospital, Kerman University of Medical
Sciences, Kerman; the 4Kidney Transplant Center of Namazi Hospital,
Shiraz University of Medical Sciences, Shiraz; the 5Kidney Transplant
Center of Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad;
the 6Kidney Transplant Center of Sina Hospital, Tehran University of
Medical Sciences, Tehran; the 7Department of Epidemiology and
Biostatistics, School of Public Health, Tehran University of Medical Sciences,
Tehran; and the 8Department of Physiology and Pharmacology, Pasteur
Institute of Iran, Tehran, Iran
Acknowledgements: This study was supported by Zahravi Pharmaceutical Company, Iran. None of authors has any conflicts of interest to disclose. The authors would like to thank Dr. Mohammad Reza Abbasi from the Nephrology Research Center, Tehran University of Medical Sciences, Tehran; Dr. Farrokh-Legha Ahmadi and Dr. Sepideh Seifi from Kidney Transplant Center of Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran; Dr. Shiva Seirafian, Dr. Mojgan Mortazavi, and Dr. Abdol Amir Atapour from Kidney Transplant Center of Zahra Hospital, Isfahan University of Medical Sciences, Isfahan; Dr. Abbas Etminan and Dr. Simin dokht Habibzadeh from Kidney Transplant Center of Afzali-pour Hospital, Kerman University of Medical Sciences, Kerman; for their contribution to this trial. The authors are also grateful to all the study patients for their commitment to this study.
Corresponding author: Professor Mohammad Sayyah, Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran
Phone: +98 21 6696 8854
Fax: +98 21 6696 8854
Figure 1. Disposition of Patients
Table 1. Patient Characteristics
Table 2. Cyclosporine Levels
Table 2. Cyclosporine Levels
Figure 2. Kaplan-Meier Curve Estimation of Probability of an Occurrence of Acute Rejection
Table 3. Rates of Acute Rejection
Table 4. Serum Creatinine Levels
Table 5. Adverse Effects
Table 6. Hospital Readmission of Patients